Skip to main content
. Author manuscript; available in PMC: 2021 Oct 15.
Published in final edited form as: Cancer Res. 2021 Feb 16;81(8):2086–2100. doi: 10.1158/0008-5472.CAN-20-2218

Figure 7. Therapeutic targeting of DGKA decreases alveolar airspace enlargement in a preclinical model of LAM and prevents cyst formation in a model of TSC.

Figure 7.

(A) Mean linear intercept quantification shows that DGKA downregulation decreases the alveolar airspace in lung sections from NCr mice injected with 3 million shDGKA (n=4 mice) or shCTL (n=5 mice) TTJ cells. (B) H&E stained lung sections from mice injected with shCTL or shDGKA TTJ cells. (C) Body weight of mice injected with shCTL TTJ cells decreased by 20% 19 days after injection. (D, E) Ritanserin (20mg/kg/daily) reduced the number of lesions and overall tumor burden of Tsc2+/− A/J mice after 30 days of treatment. (F) H&E stained kidney sections from mice treated with vehicle (upper panels) and ritanserin (lower panels). Data are represented as mean +/− standard deviation and statistical significance was assessed using unpaired t-test with *p<0.05.